The notices it replaced
- Reissues: PAR-07-184 Innovative Therapies and Clinical Studies for Screenable Disorders (R01)
- 2 steps back: PAR-06-060
Replaced by PAR-14-270.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,475,973 in first-year total cost, median $397,163.
Most frequent study sections
- Special Emphasis Panel[ZRG1 GGG-Q (50)]3
Most frequent institutions
- BOSTON CHILDREN'S HOSPITAL2
- RESEARCH INST OF FOX CHASE CAN CTR1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia1R01HD076258-01A1 | GRANT, PATRICIA ELLEN | BOSTON CHILDREN'S HOSPITAL, MA | $714,129 | ZRG1 |
| 2014 | Treatment of CBS Deficiency with Proteostasis Modulators1R01DK101404-01 | KRUGER, WARREN D | RESEARCH INST OF FOX CHASE CAN CTR, PA | $397,163 | ZRG1 |
| 2014 | Genetic screening and therapies for nemaline myopathies1R01HD075802-01A1 | BEGGS, ALAN H. | BOSTON CHILDREN'S HOSPITAL, MA | $364,681 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.